0.30Open0.30Pre Close0 Volume6 Open Interest15.00Strike Price0.00Turnover576.15%IV104.00%PremiumAug 30, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.1691Delta0.0601Gamma25.00Leverage Ratio-0.1460Theta0.0001Rho4.23Eff Leverage0.0018Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet